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Abstract
Heart failure is a common and debilitating disease with about 40 million affected world-
wide. While there has been some improvement in the optimal medical therapy over the 
last two decades there is a worldwide stagnation in the number of heart transplantations 
which is only available to a very few selected patients. The emergence and progress in 
mechanical circulatory support strategies over the same period has provided a real hope 
for those patients who have otherwise similar life expectancy to terminal cancer patients. 
Devices like the IABP have been around for longer but it was the advent of extracorpo-
real pulsatile and especially the so-called second and third generation ventricular assist 
devices that provided a real progress in the surgical treatment of heart failure. Devices like 
the HeartMate II and the HeartWare MVAD found widespread application as intracorpo-
real continues-flow left ventricular assist devices. Initially the licences were for bridge to 
transplantation but more and more patients are now receiving these devices as destina-
tion therapy. There are certain specific complications like device thrombosis, bleeding and 
driveline infection that are related to these devices and are the focus of current research 
and development so that over the next decade or so that we can anticipate that newer 
devices may provide a direct alternative to transplantation with the advantage of its avail-
ability off the shelf. The ensuing increased usage of these devices will possibly reduce the 
cost to more affordable rates for the health care providing institutions worldwide which 
will make them available to millions of patients who have otherwise a very bleak outcome.
Keywords: heart failure, heart transplantation, mechanical circulatory support, 
ventricular assist devices, VAD complications
1. Introduction
Heart failure (HF) is a common condition affecting 37.7 million people worldwide. In majority 
of affected patients it can be debilitating chronically if not immediately lethal in some. The bur-
den on the affected individual as well as the wider society is considerable. Currently the best 
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available treatment for worsening end-stage HF despite optimal medical therapy is considered 
to be heart transplantation with the caveat that it is available for only very few patients who are 
deemed eligible to be accepted on the waiting lists and survive long enough without precluding 
end-organ dysfunction for a suitable organ to become available. For the rest the outcome is very 
poor with an average survival of 50% at 5 years after diagnosis of HF, rates comparable with the 
diagnosis of cancer. While early extra-corporeal pulsatile mechanical circulatory support has 
been around since 1960s, it was the advent of continues flow intra-corporeal ventricular assist 
devices (VAD) that made this treatment widely available as longer term option to advanced HF 
patients. Last decade has seen a worldwide surge in the use of long-term left ventricular assist 
devices (LVAD) that has given a new hope to patients together with new challenges. These 
challenges are based around chronic driveline infections, right ventricular failure, neurologi-
cal events and the dilemma between thrombosis and bleeding. Recently the focus of research 
and development has shifted towards alleviation of these complications and development of 
comprehensive strategies and pathways for acute and chronic HF patients.
2. Heart failure
Heart failure (HF) is one of the most common causes of death while it affects about 37.7 mil-
lion people worldwide and was identified as an epidemic in 1997 [1, 2]. In majority of patients 
it can have a debilitating effect chronically if the initial insult is survived. The burden on the 
affected individual as well as the wider society is substantial. Poor exercise tolerance, chronic 
lethargy and depression with constant anxiety of sudden death together with frequent hospi-
talizations are among those factors limiting patients’ quality of life (QOL). The burden to the 
society is highlighted by 1–4% of all hospital admissions in Europe and US being due to HF 
with an average stay of 5–10 days and readmission rates of about 25% within 1 month and 
50% within 2 months after discharge [3].
Over the last two decades the management of HF has improved with optimal medical ther-
apy including ACE-Inhibitors, β-Blockers, loop-diuretics and Spironolactone together with 
implantable defibrillators and resynchronisation devices. However the best available therapy 
for advanced HF is heart transplantation with the caveat that it is available for only very few 
patients who are deemed eligible to be accepted on the waiting lists and survive long enough 
for a suitable organ to become available. For the rest the outcome is very poor with an average 
survival of 50% at 5 years and 10% at 10 years after diagnosis of HF. This rate has not changed 
in the last 20 years whereas the survival when diagnosed with cancer has doubled in the last 
40 years. Therefore there is much potential for alternative treatment options of which the 
ventricular assist devices present a real hope.
3. Mechanical circulatory support
3.1. Emergence of ventricular assist devices
The relative short history of mechanical circulatory support in clinical use started with the 
invention of the cardiopulmonary bypass machine early 1950s that allowed safe operations 
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on the open heart. The first device to temporarily support the circulation other than for heart 
operations was reported in 1962 in the form of intra-aortic balloon pump (IABP) [4, 5]. The 
research into the development of more substantial mechanical circulatory assist devices that 
was initiated by the National Institutes of Health (NIH) in the US was responsible for most 
of the progress that followed from the 1960s onwards. Funded by the NIH we had the first 
reported clinical use of an intra-corporeal and then extra-corporeal ventricular assist devices 
in 1963 and 1966 respectively by DeBakey’s group [6]. A total artificial heart (TAH) was devel-
oped in Baylor College of Medicine and then implanted in 1969 by Cooley. Much progress 
in the following 30 years has been around sizeable extra-corporeal devices that were driven 
pneumatically with substantial consoles. These were relatively successful so-called first gen-
eration short-term devices with pulsatile flow pattern allowing patients in acute heart failure 
to bridge to recovery or transplantation but were burdened with high rates of mortality and 
morbidity. Patients were bed-bound, unable to mobilise and could only be supported for few 
days to weeks. The lack of long-term durability of these devices was the main factor to restrict 
the use only as a short-term bridge to transplantation.
The next big step towards more usable devices took shape around the millennium with a 
new so called second generation devices that were smaller therefor implantable and intra-
corporeal. These pumps provided a continues flow (CF) pattern generated by an axial rotor 
which was suspended mechanically in its casing. The lack of pulse was a shock to the medical 
community that required some debate and time to get over. These CF VADs also required 
thinner drivelines that helped to reduce the infections often originating from exit sites of 
large cannula and drive lines of the first generation devices. To date the most commonly used 
example of these devices is the HeartMate II which is still used frequently. Other rarely used 
examples were Jarvik 2000 and Micromed DeBakey VAD.
Another quantum leap happened more recently in the last decade when there was a surge in 
the number of implanted LVAD’s worldwide triggered by both the new licences obtained for 
destination therapies and particularly with further progress achieved with newer so called 
third generation devices. These devices introduced substantial progress in further miniaturi-
sation, reliability, durability and noise reduction all of which contributed to the usability and 
long-term manageability of patients who now tend to envisage living with these devices for 
the rest of their lives. Primary third generation device example is the HeartWare HVAD with 
recent addition of HeartMate 3 both of which have a centrifugal pump that is magnetically 
suspended eliminating wear-out with better durability. Miniaturisation meant that they could 
be implanted entirely intra-pericardial even on smaller adults and children.
Current research focuses in reducing the much feared morbidities. Driveline infections is 
one and often cited as the ‘Achilles’ tendon’ of LVADs. Progress in transcutaneous energy 
transmission systems (TETS) promise to avoid the need for drivelines altogether. Special 
consideration of the right ventricle (RV) is required as the vast majority of VADs is placed 
for the support of the left ventricle with early and late post-operative RV failure resulting in 
significant increase in mortality. Strategies have been developed to predict RV failure, to pre-
ventively optimise haemodynamic parameters pre-operatively and to improve management 
post-operatively. The dilemma between pump thrombosis and bleeding can be very difficult 
to manage and has to be patient specific. Usual long-term strategy involves a combination 
of warfarinisation and anti-platelet therapy that allows individual attention to patients’ 
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tendency to either “bleed” or “clot”. Another fascinating area of research is gastro-intestinal 
AV-malformations and their relationship with von Willebrand factor and CF pattern of these 
new devices. Newer materials are sought for better biocompatibility and reduced thrombo-
genic properties.
Due to the unique nature of patients and their LVADs most of established MCS Programs 
have now comprehensive long-term management protocols involving patients’ families, 
General Practitioners, local emergency departments and hospitals, ambulance services and 
local government services.
3.2. Current devices
The vast majority of currently used LVADs are the HeartWare HVAD and HeartMate 3. Both 
are miniaturised and fully implantable into the pericardial cavity and by the use of a centrifu-
gal pump that is magnetically levitated they avoid mechanical wear-out therefore more dura-
ble and less thrombogenic. The HVAD has a centrifugal pump that is magnetically levitated 
with hydrodynamic bearings avoiding mechanical interface resulting with only one moving 
part that is the pump which is driven by two motors providing a continuous flows of blood. 
The HVAD System weighs at 160 g and is small enough to fit intra-pericardial in most patients 
with dilated cardiomyopathy. There have been reports of two pumps for bi-ventricular sup-
port and some paediatric use to ages below 10 years all of which placed fully intra-pericardial 
[7–9]. Only some restrictive cardiomyopathy and smaller children present a challenge due to 
lack of intra-pericardial space. The HeartMate 3 is similar in design and function with certain 
differences. These include full magnetic levitation without hydrodynamic bearings allowing 
for the rotor to operate in wider RPM ranges which in turn allows flows between 2.5 and 
10.0 L/min and larger gaps between the rotor and the casing reducing the haemolysis and 
sheer stress to the blood. There is also an attempt to address the concerns about CF in regards 
to its causative effects on AVM’s by incorporating a degree of pulsatility to the flow profile. 
The Abiomed Impella device is a different approach which includes the option of percutane-
ous insertion and placement across the aortic valve with blood inlet area in the LV cavity and 
outlet area in the ascending aorta reaching flows up to 5 L/min. An axial rotor is positioned 
at the outlet area. Common complications include haemolysis, device thrombosis, bleeding, 
vascular injury and arrhythmia [10, 11]. There are numerous other short- and long-term ven-
tricular assist devices available however these are less frequently used by the majority of 
centres specialising in MCS.
3.3. Patient selection
Each patient in heart failure requires individualised assessment for suitability for MCS 
implantation which proposes only one aspect of patient management. Patient and device 
choice depend on the indication and purpose of the MCS implantation. Statistically over the 
last decade the majority of patients treated with assist devices fall in to Intermacs classes 1–4. 
Table 1 describing severity of heart failure according Intermacs classification (Interagency 
Registry for Mechanically Assisted Circulatory Support) and expected survival of patients 
in each category which helps to determine the urgency of the intervention as well as its type.
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Level 1: patients in this category usually present with fulminant myocarditis or more com-
monly after complicated myocardial infarction when primary PCI failed to restore the result-
ing acute loss of pump function of the heart. If there is sufficient evidence that the individual 
would be suitable transplant candidate than a longer term MCS could be considered but in 
reality in this emergency setting this evidence is lacking so that in most cases short-term MCS 
device is chosen as salvage and bridge to decision. Devices to consider for these patients 
include intra-aortic-balloon-pump (IABP), extra-corporeal-membrane-oxygenator (ECMO) 
or more recently the Impella device or TandemHeart. While the application of ECMO usually 
requires a dedicated centre, the insertion and management of IABP or Impella is less cumber-
some but only provide partial support of the circulation. Occasionally the Impella device is 
also used for right ventricular support either in addition to the left sided support or in isola-
tion. There are reports from highly specialised ECMO centres achieving relatively high sur-
vival rates for ECMO application on patients with out-of-hospital-cardiac-arrest (OOHCA) 
and ongoing CPR [12].
Level 2: these patients are deteriorating despite escalating inotropic support and usually 
show end-organ dysfunction and not expected to survive more than days or weeks. They 
are either unfit for transplantation due to end-organ dysfunction or not expected to survive 
long enough for a suitable donor-heart to become available. Considerations for Level 2 pat-
ents include destination therapy or bridge to either decision or candidacy/transplantation. 
Devices for this category include HVAD or HM3 among other less often used devices as well 
as even less commonly used total artificial heart systems (TAH). More common than TAH is 
the temporary support of the right ventricle with extra-corporeal CentriMag in addition to an 
LVAD. If there is complicating respiratory dysfunction, it is easy to add an oxygenator to the 
CentriMag circuit and await recovery.
Intermacs 
level
Short code Definition Expected survival: action required
Level 1 “Crash-and-
burn”
Critical cardiogenic shock, oliguria/anuria, 
rising lactate levels and liver function tests
Hours/days: immediate intervention 
required
Level 2 “Sliding fast” Progressive decline despite inotropic 
support
Days/weeks: intervention within days
Level 3 “Hospital 
bound”
Stable but inotrope dependent Weeks/months: elective MCS vs. 
Transplant within weeks
Level 4 “Frequent flyer” Resting symptoms, frequent hospitalisation 
with decompensation
Months/year: elective MCS vs. 
Transplant
Level 5 “House bound” Comfortable at rest, intolerant to minimal 
activity of daily living
Year/s: elective MCS vs. transplant 
depends on other parameters
Level 6 “Walking 
wounded”
Exertion intolerant, can only manage 
normal activity of daily living
Year/s: elective MCS vs. transplant 
depends on other parameters
Level 7 NYHA III Advanced NYHA III Years: medical management, MCS or 
transplant not indicated
Table 1. Intermacs classification with definitions and management strategies.
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Level 3 and 4: these patients have a very poor quality of life being either hospital bound or 
admitted frequently. They also often have end-organ dysfunction that precludes them from 
listing for transplantation. If they are suitable for transplantation and have preferable blood 
group/typing and body weight and if the geographical donor pool is preferable making heart 
transplantation likely within few weeks or months then waiting for transplantation may be a 
good option. However in reality in most centres in the world overcoming all of these postula-
tions and receive a successful heart transplantation is preserved to a very few lucky ones. In 
vast majority patients at this level of disease progression present considerable disease burden 
and require MCS in an elective fashion. Left ventricular support with HVAD and HM3 are 
most commonly used. In patients with concomitant right ventricular dysfunction there are 
different approaches available. Mostly, pre- and post-operative optimisation and attentive 
management of the body fluid equilibrium are sufficient to prevent right ventricular failure. 
Sometimes a temporary RVAD with CentriMag is required to overcome the immediate intra- 
and post-operative insult to the right ventricle. A right sided Impella is also an option in this 
setting.
Level 5 and 6: patients at these levels of disease progression are usually stable in the short 
and medium term period therefore could be placed on heart transplant waiting lists with 
close follow up to early pick up any sign of deterioration or end-organ dysfunction. Some 
patients in this category present or develop pulmonary hypertension precluding them from 
listing for transplantation which can be improved with an LVAD therapy rendering them into 
a candidacy position. Generally these patients are not considered for MCS as the heart failure 
burden is comparable with the burden of any type of mechanical support is often accompa-
nied. In the coming years this cohort of patients will become increasingly the focus when we 
can significantly reduce the frequently observed complications related to MCS.
3.4. Peri-operative management
End-stage heart failure with diminished organ perfusion has a detrimental effect to most of 
organ systems of the body. Renal dysfunction due to reduced cardiac output, liver dysfunc-
tion due to cardiac output as well as congestion, nutritional depletion due to dysfunctional 
gastrointestinal absorption as well as liver dysfunction causing physical debilitation, respira-
tory dysfunction due to congestion as well as pulmonary hypertension, upwards regulation 
of the systemic inflammatory responses, cognitive impairment due to hypoxia and psycho-
logical implications due to constant anxiety and burden of the disease all contribute to push 
the individual into a vicious circle and downwards spiral of end-stage heart failure. Any MCS 
system aiming to alleviate the underlying cardiac dysfunction is bound to fail if these organ 
systems are not concomitantly addressed.
Aggressive fluid removal with high dosages of loop-diuretics and/or renal replacement 
therapy in form of haemofiltration may be required on top of optimal medical therapy which 
includes β-Blockers, ACE-Inhibitors and Spironolactone. The achievement of the ideal fluid 
equilibrium sets the right ventricle in a best possible starting position to overcome the strains 
of the operation and the increased cardiac output that will be provided by the LVAD. The 
use of infused phosphodiesterase inhibitors and inhaled nitric oxide can support the right 
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ventricle in this immediate post-operative period. Cardiac arrhythmia needs to be treated 
aggressively for the same purpose.
Intensive input from the dietitian as well as physiotherapist and psychologist represent cor-
nerstones of optimal pre- and post-operative management of patients receiving MCS.
3.5. Surgical techniques
The urgency of the procedure and the type of MCS together with the individual clinicians 
and units experience determines the technique of implantation. Of course there are different 
approaches to the implantation technique including bilateral small thoracotomies, avoidance 
of the CPB, using more distal aortic sites for outflow-graft anastomosis and exit point of the 
drive-line. We will however only discuss the most common approaches of the techniques 
related to the implantation of the most commonly used devices.
The simple percutaneous insertion of IABP does not require much attention due to its com-
mon use and familiarity. The Impella device is inserted percutaneously through the femoral 
or subclavian/axillary arteries with the help of Fluoroscopy and cardiac catheterisation tech-
niques. The blood inlet area is at the tip of the device which is positioned across the aortic 
valve in the left ventricular outflow tract well away above the papillary muscles and the outlet 
area is positioned well above the aortic valve at the level of the sino-tubular junction. Trans-
oesophageal Echocardiographic images help exactly position the inlet and outlet areas.
For the implantation of the HVAD the patient is positioned supine and draped exposing the 
entire front of the trunk including cranially the jugular notch and medial two thirds of the clav-
icles for the exposure of the subclavian vessels, laterally along the anterior axillary line down to 
the anterior superior iliac spinosus and further down the lateral thigh and caudally just above 
the patella. The groins are kept prepared in case femoral cannulation is required for ECMO or 
additional RVAD support. Standard median sternotomy and ascending aortic and right atrial 
cannulation is performed for cardiopulmonary bypass (CPB). Techniques avoiding median 
sternotomy therefor avoiding the need for re-do sternotomy for eventual heart transplantation 
includes left anterior thoracotomy at the apex which can be localised with TTE, and right para-
sternal thoracotomy at 2nd ICS can be used with or without CPB. The LV apex is examined and 
the dimple identified to centre the sewing ring around just lateral to the distal LAD. We use 16 
pledged 4/0 Prolene sutures in a horizontal mattress fashion and a layer of sealant to secure the 
sewing ring in position. Then while the heart is fibrillated a cross incision with a blade is made 
and the coring device provided in the implantation pack is used to remove a cylindric piece of 
myocardium within the sewing ring. The HVAD device is then inserted into the sewing ring 
and fastened with the screw driver provided. The inflow cannula is oriented directly pointing 
to the middle of the mitral valve which is confirmed with TOE images. The outflow graft is left 
open momentarily for de-airing. The outflow graft is then sutured with continues 5/0 Prolene 
sutures just like any other top-end anastomosis right laterally onto the ascending aorta above the 
ST junction and above the SVC using a side-biting clamp. The clamp on the graft can again be 
released momentarily before tying the knot for further de-airing of the LV. The driveline can now 
be tunnelled across the abdominal wall with three exit points in a Z-shaped or V-shaped course 
initially sub-fascial then subcutaneous. The final exit point is at the level lateral and below the 
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umbilicus either on the right or the left flank depending on patients’ handedness and preference 
which is usually determined pre-operatively if possible. After the driveline is connected to the 
driver CPB is discontinued slowly and the HVAD started and RPMs set that allow the inter-ven-
tricular septum to be straight and neither bulged to the left nor to the right. TOE is used to assess 
the septum as well as right ventricular function and aortic valve opening. Volume load, inotropic 
support, especially Milrinone, inhaled nitric oxide and setting of the RPMs of the LVAD can help 
to fine tune the patients’ haemodynamic equilibrium and prevent RV failure. This is usually the 
timing for the decision to add an RVAD is made. The implantation of the HM3 is very similar 
with that of the HVAD with only little differences owing to the design of the pump.
If there is the need for temporary RVAD then CentriMag is often used as extracorporeal cen-
trifugal VAD using the femoral venous cannulation for inflow and a Gore-Tex vascular graft 
onto the pulmonary artery and tunnelled through the left second intercostal space paraster-
nally and above the pectoral muscle with any aortic cannula attached as outflow. If a more 
long-term RVAD is required then another HVAD can be used in intra-pericardial position 
using inferior RV wall or the RA as inflow access and the PA as outflow. The use of TAH could 
also be considered however the evidence for long-term TAH is scanty.
3.6. Complications
We will investigate not the common complications related to any heart surgery but only 
those particular to VADs. These include drive-line infections (DLI), pump thrombosis (PT), 
GI-bleeding, cerebral vascular incidents, right ventricular failure and aortic valve insufficiency.
3.6.1. Driveline infections
Overall DLI incidence is around 10–20% with higher rates observed with devices requiring a 
pump-pocket or has larger diameter drivelines [13]. This rate is also dependent on patient and 
procedure risk factors including hygiene, nutritional status, diabetes, urgency of the procedure 
and implantation technique. Prolonged subcutaneous course is thought to prevent speedy up-
migration of potential DLI towards the pump itself with severe consequences however at the 
same time it increases the potential infection sites by increasing the number of skin breakages 
to allow the long course. The use of antibiotic containing products deposited at the exit site may 
also help reduce the infection rate. The burial of the Dacron part of the DL below the skin allow-
ing only silicone-skin interface as well as perpendicular exit of the DL as supposed to lying 
on the skin can further help reduce the DLI rates. Treatment includes targeted antimicrobial 
therapy and surgical exploration with debridement and re-routing of the DL. Long-term sup-
pressive antimicrobial therapy is a not too unfeasible option to control and contain infections 
that are difficult to eradicate or too close to the pump and carry high risk for operative approach.
3.6.2. Anticoagulation
Patients present with different levels of general coagulability, which is why there are rather 
non-scientific terms like “clotter” and “bleeder” in existence and in use in the clinical arena. 
The general state of the patients nutrition and rates of systemic inflammatory response to 
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heart failure as well as to the operative insult has surely more influence to the coagulation 
tendencies. The resistance to acetylsalicylic acid (ASA) is another more scientific explanation 
why some patients do not respond to platelet inhibition with Aspirin therefor more prone 
to thrombosis. Previous events of thrombi especially in the left ventricular cavity or in the 
left atrium predispose to pump thrombosis. Device type also seems to influence the rates of 
thrombosis although not proven to be statistically significant. Increased thrombosis is also 
seen if for clinical reasons lower pump-flow rates are sought with corresponding low RPMs of 
the device. Consideration to all of the above together with a thrombophilia workup will allow 
an individualised anticoagulation regimen that requires close monitoring with the available 
methods. The usual anticoagulation regimen that can be the basis includes initial heparinisa-
tion started after 12–24 h postoperative depending on chest tube drainage. Heparinisation is 
guided by activated clotting time (ACT) at 160–220 s. On postoperative day one Aspirin at 
around 150 mg can be introduced and later increased to 300 mg per day in single or divided 
doses. Aspirin response can be measured and monitored with serum anti-Xa levels with a 
therapeutic target range of 0.5–1.0. Aspirin can be supplemented or replaced with Clopidogrel 
for resistance or allergy. Dipyridamol is often added to this anti-platelet regimen. Warfarin is 
introduced on day three or later depending on chest tube drainage and presence of epicardial 
pacing leads which require removal. The recommended target INR is between 2.0 and 3.0 for 
most devices.
Surveillance of anticoagulation is routinely done by INR measurements complemented by 
platelet count and serum LDH. However some centres advocate more detailed assessments 
including platelet function tests, anti-Xa levels and thromboelastogram (TEG).
3.6.3. Pump thrombosis
The diagnosis of pump thrombosis is suspected primarily if there is increase in pump power 
with or without pump flow changes. This is due to the fact that the driver has to spend more 
power to achieve same speed of the rotor which is impeded by the presence of the thrombus 
either reducing the blood inflow into the cannula or through the pump or the outflow graft or 
indeed mechanically impeding the rotation of the rotor inside the pump in areas of the rotor 
bearings. Further diagnostic test is the serum LDH levels which increase relative to baseline 
surveillance levels. Clinical signs i.e. haematuria, of or laboratory tests for haemolysis the 
likes of haptoglobin, plasma-free haemoglobin, bilirubin and fibrinolysis products can aid the 
diagnosis. If the pump thrombosis is large enough to cause reduction of pump output signs 
of heart failure can resurface. Cardiac imaging with Echocardiogram and/or CT Thorax for 
visualisation of the thrombus in the ventricular cavity as well as assessment of ventricular fill-
ing together with manipulation of the pump speed can be carried out for further differentiate 
the diagnosis.
Treatment of device thrombosis depends on the severity of the thrombus and its haemody-
namic and device related complications. This would include up-regulation of anticoagula-
tion, intravenous heparinisation, systemic thrombolysis or device exchange if the former 
interventions are not successful. New approaches with intra-ventricular and/or intra-pump 
thrombolysis and washout are being assessed for safety and effectiveness.
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3.6.4. Gastro-intestinal bleeding
Intractable epistaxis is mentioned but not further discussed here as often this can be managed 
successfully with the input of ENT Surgeons. There are several reports and studies investigat-
ing bleeding from the entire gastro-intestinal tract (GIT). Obvious predisposing risk factors 
include reflux oesophagitis, gastritis or inflammatory diseases like Crohn’s or Colitis which 
may present themselves as contraindication for VAD therapy as they will be very difficult if 
not impossible to manage with full anticoagulation. More intriguing concept in continues 
flow (CF) LVAD therapy is the often encountered arteriovenous-malformations (AVM) that 
seems to be associated with von Willebrand factor (vWF) deficiency. There are theoretical and 
conceptual suggestions that the continues flow pattern of these devices are at least partially 
responsible for development of AVM’s in the GIT. Simultaneously the accelerated speed of 
the blood through the rotors of these CF pumps is said to be responsible for high shear forces 
active on the high molecular weight vWF causing distortions/breakages leading to qualitative 
changes with subsequent reduction of function in relation to platelet aggregation. This com-
bination of AVM’s with vWF deficiency gives rise to intractable bleeding occasionally leading 
to surgical intervention.
3.6.5. Cerebral vascular incidents
Intracerebral events are feared for the reason that they are often fatal. They can be of two 
sometime overlapping pathophysiology namely embolic or haemorrhagic of nature. Embolic 
events are more often encountered peri-operatively due to particulate matter or air from the 
operative field reaching cerebral vasculature causing ischaemia. The particulate emboli can 
originate from preexisting thrombi from the LV or LA cavity, atherosclerotic debris from 
the aortic manipulation during cross clamping or graft anastomosis or paradoxical thrombi 
crossing across an undiagnosed ASD. Therefore great care is taken in pre-operative workup 
to identify these risk factors. Air emboli can be avoided with appropriate and assiduous de-
airing manoeuvres aided by CO
2
 insufflation of the operative cavity. Later in the follow up 
period haemorrhagic intracerebral events predominate in frequency and lethality although 
often overlapped with embolic events that transform into haemorrhagic lesions.
3.6.6. Right ventricular failure
Management of the right ventricle in patients receiving LVADs can present itself like a 
manoeuvre ‘between Scylla and Charybdis’. Bi-ventricular assist device implantation has 
reportedly high mortality therefore efforts are focused into avoidance of RVAD in addition to 
LVAD therapy if at all possible [14–17]. Strategies have been developed over the last decade 
that include optimisation of hydrostatic status of the heart failure patients including oral and 
intravenous pharmacological as well as renal replacement therapies. This effort aims to set 
the right ventricular filling pressures into the optimal position on the Frank-Starling Curve 
with the best possible contractility resulting from the actin-myosin relationship. In practice 
this means to aim to decrease the central venous pressure down to single figures i.e. below 
10 mmHg prior to the procedure if there is sufficient time available. Further fluid can be 
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removed using haemofiltration during cardiopulmonary bypass if used. Other peri-operative 
measures include off-pump and minimally invasive techniques to minimise systemic inflam-
matory response to the procedure, TOE guided optimisation of the position of the ventricu-
lar septum by manipulation of the LVAD speed and the use of pulmonary arterial pressure 
attenuating pharmacology including intravenous phosphodiesterase inhibitors and inhaled 
nitric oxide. Comprehensive heart rhythm management including resynchronisation and 
anti-arrhythmic strategies are required to avoid the undesirable effects of arrhythmia to RV 
function. Hybrid approaches of endocardial and epicardial ablation for supra-ventricular or 
ventricular arrhythmias may represent a feasible option in some centres. Continued effort is 
necessary in the long-term follow up of these patients focussing on hydrostatic optimisation 
if the right ventricular function is to be kept under control.
3.6.7. Aortic valve insufficiency
The evidence is mounting that show the adverse effect of the continues flow LVADS to the 
aortic valve [18–22]. Constant closure of the valve during LVAD support encourages fusion 
of the leaflets leading to stenosis. More importantly the lack of physiological movements of 
the leaflets during the cardiac cycle leads to worsening of mild to moderate regurgitation 
with increased morbidity. Over time an increasing portion of the pump flow returns back to 
the LV cavity creating a short circuit with resulting peripheral hypo-perfusion and LV filling 
pressures consequently return of heart failure symptoms. Manipulation of pump speeds to 
achieve sufficient aortic valve opening is proposed by large MCS Centres. Bioprosthetic aortic 
valve replacement for more than mild aortic regurgitation at the time of LVAD implantation 
has been advocated by experts more frequently in recent years.
3.7. Long-term management
The patient population with long-term LVAD therapy has been increasing due to the 
improved technology and the management strategies of the complications. More patients are 
now receiving LVADs as de-facto destination therapy as there is no other promising treatment 
option available for patients who do not belong to the lucky few transplant recipients. This 
increasing population require close and continued care that is very distinct and individual-
ised. A great number of regional health care services, social services and potentially family 
and friends need to be involved in the care of these patients. Local emergency services and 
hospitals need to be familiarised with the specific patient profiles. They need not to panic and 
commence CPR if there is no pulse. They need to know that some arrhythmia is better toler-
ated than without an LVAD, that deranged anticoagulation does not always require immedi-
ate counter measures, that any infection/sepsis can have amplified detrimental effects on RV 
function and anticoagulation and that their hydrostatic equilibrium may have a very small 
margin of safety. Social services and local council authorities have to facilitate emergency 
measure for power cuts. Relatives and friends or carers need to familiarise themselves with 
the LVAD driver connections to the drive-line, batteries and power cables and what certain 
alarms mean and how to contact the appropriate MCS Centre. This close monitoring and 
cooperation can only be achieved with dedicated VAD coordinators taking on a central role 
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between the patient and their carers, the clinicians and local emergency and social services. 
Well thought through protocols taking into account the geographic particularities and cir-
cumstances are required to accommodate the needs of this distinct group of patients that is 
certain to grow in numbers in the not so far future.
4. Future developments
The technology around mechanical circulatory support is evolving with an exponential speed 
which makes any prediction beyond few years futile. We can however look into current work 
that is focusing in the alleviation of VAD complications and is promising to become clinical 
practice in foreseeable future. One of these is contactless energy transfer that is combined with 
subcutaneous implantable batteries allowing transcutaneous energy transfer (TET) and avoid 
the driveline passing through the skin eliminating the ‘Achilles’ heel’ of MCS Systems [23]. 
Further work involves strategies aiming for early and more sensitive recognition and treat-
ment of certain complications especially the likes of pump thrombosis. These techniques use 
remote monitoring systems with in-time assessment and intervention of pump readings and 
parameters to more finely tune the VAD therapy [24]. Improved biocompatibility of materials 
used and rotor design will surely be helpful to reduce thrombosis risk as well as to reduce 
shear forces affecting blood components. Further miniaturisation and less invasive techniques 
of implantation can be expected to become more common place in the near future and will 
allow to expand the age spectrum of the recipients. Better understanding and management 
of right ventricular dysfunction may be coupled with more intuitive bi-ventricular support 
in order to achieve better and sustainable results. With improved results and better control of 
complications one can expect to broaden the spectrum of recipients to less sick patients and 
include Intermacs classes 5 and above to preemptively avoid end-organ dysfunction of heart 
failure patients.
5. Conclusions
Within a relatively short period of emergence the implantation of left ventricular assist devices 
have made a huge impact in treatment of end-stage heart failure patients. The development 
of a new treatment method inevitably brings with it new challenges that limit its spectrum of 
utilisation. LVAD specific challenges which represent the limiting factors are mainly driveline 
infections, anticoagulation balances, cerebral incidents and right ventricular dysfunction. We 
can be optimistic that current research will lead to progress in tackling of these challenges so 
that we will be able to claim that this therapy method represents a first line management plan 
for HF patients. Notwithstanding the recent encouraging attempts of widening the donor 
pool to donation after circulatory death, the number of heart transplantation worldwide has 
reached a plateau and is only available to very few select types of patients. The prospect of 
much improved mechanical support methods for the circulation with better manageability 
represents a real hope for patients in wider age spectrum as well as in earlier phases of disease 
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progression. Sooner or later MCS Systems that are available off the shelf and adaptable to 
each patients needs have the potential to replace heart transplantation for end-stage heart 
failure. However we may want to mention here that in parallel there are endeavours in bio-
engineering and gene-manipulation which could allow speculations into the ‘off-the-shelf’ 
availability of authentic spare organs for each person.
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